1 / 15

Miquel Àngel Bonachera, Founder and CEO-CFO

Miquel Àngel Bonachera, Founder and CEO-CFO. TABLE OF CONTENT. AB-BIOTICS COMPANY BASICS FOUR BUSINESS UNITS SHAREHOLDERS AND MAB BASICS ADVANTAGES OF BEING LISTED IN MAB TAX BENEFITS EFFECT ON AB-BIOTICS IPO. Main advantage of MAB:

dextra
Télécharger la présentation

Miquel Àngel Bonachera, Founder and CEO-CFO

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Miquel Àngel Bonachera, Founder and CEO-CFO

  2. TABLE OF CONTENT • AB-BIOTICS COMPANY BASICS • FOUR BUSINESS UNITS • SHAREHOLDERS AND MAB BASICS • ADVANTAGES OF BEING LISTED IN MAB • TAX BENEFITS EFFECT ON AB-BIOTICS IPO Main advantage of MAB: When you can be found at Bloomberg you are ready to go global.

  3. AB-BIOTICS

  4. BUSINESS DEVELOPMENT - PROFITABILITY +

  5. Business Development • New shareholders: • Business Angels • Venture Capital • Out-LicencingColls. • Board members that shall give us Experience. • Know-How • Know-Who - PROFITABILITY +

  6. AB-BIOTICS • Project Management R&D projects for companies. Main clients belong to the Food Functional and Food supplements. • Historic 5 years in operation and constant growth. • In company R&D for development of functional ingredients, mainly probiotics for application in functional foods and food supplements. • Company subsidiary dedicated to the development of advanced genetic tools for Medical Diagnosis (SNP, CNV) • The company has appropriate human and technical resources to conducting genetic analysis. • Subsidiary dedicated to developing a braking approach in oncology: membrane-lipid therapy. • Partnerships with laboratories at Drug Discovery to ensure the inclusion of new molecules in the future.

  7. FOUR BUSINESS UNITS, TWO BUSINESS MODELS Cash-Flow Ingresos Cash-Flow Ingresos

  8. HISTORY OF THE COMPANY 2004 2005 2006 2007 2008 2009

  9. BUSINESS ANGELS ROUND 23/04/2004 EV: 81.000€ 30/07/2008 EV: 5.000.000€

  10. ADVANTAGES OF BEING LISTED IN MAB financial press.

  11. SHAREHOLDERS Market Cap €12,7MM IPO in MAB 20-07-2010 2,53€ Last Trade 23-11-2010 3,00€ Investment Resarch Q4 3,45€ Market Cap €16MM Symbol: ABB:SM ISIN: ES0109659013

  12. ENTERPRISE VALUE & SHARE PRICE risk-returntradeoff 12.690.227€

  13. ENTERPRISE VALUE & SHARE PRICE • Risk will not change, thus starting from a low valuation will maximize the chances our investors earn money. • You know when is a good value when you look forward to minimize the resources to get as well as you think of debt to buy more shares. AB-BIOTICS founders compromised 26% of total IPO new shares emission (900.000€). • Proceeds are to be used in the company. Investor gets confidence if founders buys new shares. If the offering is to professional investors, then unsophisticated investors have somehow an “expert opinion”. • Investor has to earn money always. Even if the company underperforms the business plan. If AB-BIOTICS would perform on 30% of its expected profitability, our investors would get 4x return on investment in 5 years.

  14. TAX BENEFITS Mr. Andreu Morillas i Antolín. Secretari d’Economia del Departament d’Economia i Finances de la Generalitat de Catalunya. If 1.100 (PwC) of 5.000 (Everis) would IPO in the same conditions than AB-BIOTICS, 50.000 to 300.000 new direct employments would be created in Spain during the next 3 years. 20% TAX BENEFITS for Investors in IPOs to MAB Limited to 50.000€ investment. Only private investors. Investors have to keep their position for 24 month. • 2/3 of new investors where from Catalonia (where tax benefits are settled). • Most of this investors should be willing to keep their position. • Company stability on the first period because less shares will be offered. • Lesser risk for the investors. With TAX BENEFITS: Same Risk, higer returns to the investors.

  15. 23-Abril-2004 20-Julio-2010 Miquel Àngel Bonachera Co-Founder, CEO-CFO miquel@ab-biotics.com 902 903 844 +34 972 183 421 Thank You!

More Related